The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Trump savages Taylor Swift in fresh social media barrage as president emerges the real Super Bowl winner; What did Taylor Swift say after getting booed at Super Bowl 2025? Lip rea ...

Hims & Hers' Super Bowl ad for unapproved weight loss drugs faces backlash from health experts over safety concerns.